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Background & aims: Sepsis is characterized by a systemic dysre-
gulated inﬂammatory response and oxidative stress. A large body
of evidence supports a key role of mitochondrial dysfunction
during the various phases of sepsis (early and late-phase of sepsis-
associated multiorgan failure). Coenzyme Q10 (CoQ10) is a key
cofactor in the mitochondrial and respiratory chain, and is
depleted in septic shock patients. However its effect on acute
sepsis remains unexplored. The reduced form of CoQ10 (Qx) has
been shown to lessen pro-inﬂammatory response in macrophages
or ﬁbroblasts in culture. The aim of the study is to investigate the
effect of Qx on hepatic inﬂammation in models of acute LPS-
induced inﬂammation.
Methods: We have conducted 2 experiments: one in vitro using rat
precision-cut liver slices (PCLS) incubated with LPS and Qx, and
one in vivo experiment using mice fed with Qx for 2 weeks and
killed 1 h after LPS administration.
Results: LPS challenge induced hepatic inﬂammatory stress both
in vitro and in vivo (increased TNFa, nitrite and PGE2 release and/
or expression). Incubation of PCLS with Qx fails to modulate he-
patic inﬂammatory stress. Furthermore, Qx supplementation is not
able to counteract hepatic LPS-induced acute inﬂammation in vivo.n Research Group, Louvain Drug Research Institute, Universite catholique de
ussels, Belgium.
(N.M. Delzenne).
r Ltdonbehalfof EuropeanSociety forClinicalNutrition andMetabolism. This is
e (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A.M. Neyrinck et al. / Clinical Nutrition Experimental 1 (2015) 10e18 11Conclusion: Coenzyme Q10 is not able to counteract LPS-induced
hepatic acute inﬂammation.
© 2015 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Severe sepsis and septic shock are major causes of morbidity and mortality. Among the tissues
involved in the inﬂammatory response to sepsis, the liver plays a central role in response to inﬂam-
matory stresses. Liver immune cells are able to recognize bacterial components such as lipopolysac-
charides (LPS) e the major Gram negative bacteria membrane component. In particular, Kupffer cells,
known as fundamental macrophages, are involved in LPS detoxiﬁcation and their stimulation leads to
the secretion of inﬂammatory mediators such as tumor necrosis factor a (TNFa), prostaglandin E2
(PGE2), and the reactive intermediates NO$[1e5].
Coenzyme Q10 (CoQ10) is an effective endogenously synthesized-lipid soluble antioxidant, acting
either by prevention of lipid peroxidation (chain-breaking), by regeneration of vitamin E or by inter-
action with superoxide or other reactive oxygen species. CoQ10 is a key component of the oxidative
phosphorylation process in the mitochondria [6e9]. The major form of CoQ10 found in the living or-
ganism is the reduced form, ubiquinol (Qx), responsible for its antioxidant properties [10,11]. Apart
from its anti-oxidative function, CoQ10 appears to modulate immune functions by largely unknown
mechanisms. The potential anti-inﬂammatory effect of CoQ10 or its reduced form has been suggested
through in vitro studies, showing a decrease in IL-1 induced inﬂammation in human ﬁbroblast and a
decrease in the LPS-induced release of TNFa proinﬂammatory cytokines in human and animal mac-
rophages [8,12e14]. Schmelzer et al. also showed anti-inﬂammatory properties of Qx in vitro on the
human monocyte cell line THP-1 (at a dose of 10 mM) on TNFa, macrophage inﬂammatory protein-1a,
MIP1a, and RANTES release in the incubation medium after an LPS challenge [15].
In order to investigate the potential role of CoQ10 as an anti-inﬂammatory compound during acute
sepsis, we have tested the potential modulation of acute hepatic inﬂammation induced in vitro in rat
precision-cut liver slices (PCLS). The PCLS model was chosen because it allows to keep functional the
different cell types-including immune liver cells- and respects the cellecell interactions occurring in
the liver tissue in vivo [1,3]. Moreover we have tested the role of Qx oral supplementation on hepatic
LPS-induced inﬂammation in vivo in mice 1 h after the injection of 0.1 mg/kg body weight LPS.
2. Material and methods
2.1. Reagents
LPS and bovine serum albumin were purchased from Sigma Chemical Co (St. Louis, MO, USA).
Waymouth medium, penicillin, streptomycin and glutamine was purchased from Gibco-invitrogen
(Belgium). Qx was provided by Kaneka (Japan). Aspartate aminotransferase (AST) activity kit was
purchased from Diasys, Diagnostic system GmbH (Holzeim, Germany). PGE2 Immunoassay assay kit
(DE0100®) and Quantikine rat TNFa immunoassay kit (RTA00®) were purchased from R&D System
(UK). TriPure isolation reagent was purchased from Roche Diagnostics (Belgium, Vilvoorde). Reverse
transcription System was purchased from Promega (Leiden, The Netherlands).2.2. In vitro study on PCLS
Housing conditions were as speciﬁed by the Belgian Law of 29 May 2013, on the protection of
laboratory animals (Agreement LA 1230314). Male wistar rats (n ¼ 5) weighing 240 ge280 g were
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control diet (AO4, Safe, France).
Rat procedures were carried out under pentobarbital anesthesia (60 mg/kg body weight). Perfusion
in situ of the liver was performed with oxygenated ice-cold KrebseRinger buffer prior to liver removal.
Tissue cores (diameter 10 mm) were prepared from the freshly excised liver and PCLS (about 220 mm
thickness) were rapidly prepared in oxygenated ice-cold KrebseRinger buffer using a Krumdiek slicer
according to a procedure previously described [16,17]. After 30 min of preincubation at 4 C in Way-
mouth medium supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin, 2.4 mM glutamine,
100 nM insulin and 0.3% bovine serum albumin, PCLS were transferred into fresh medium and incu-
bation lasted for 2 or 20 h. Incubation medium was similar to preincubation medium except for 0.1%
bovine serum albumin. According to the data published by Groneberg et al., it appeared that the
optimal and non-toxic concentration of CoQ10 to study expression of genes involved in cell signaling,
metabolism and transport on isolated CaCo-2 cells was 50 mM [18]. Taking into account that we have
used a tissue culture model, which imposes diffusion to target the related cells, we have decided to use
a dose of 100 uM; at this dose, no cytotoxic effects were found in the human monocytic cell line THP-1
[15]. Therefore, PCLS were additionally incubated in the presence or in the absence of Qx (100 mM) and/
or LPS (10 mg/ml). A vial containing 2 PCLS (2 ml medium per PCLS) was used for each condition. Vials
were all saturated with 95% O2e5% CO2 and placed in a shaking water bath at 37 C. After the incu-
bation, PCLS were frozen in liquid N2, mediumwas collected and medium and PCLS were then all kept
at 20 C for further analysis.
2.3. In vivo study
Ten-week-old male C57BL/6J mice (Charles River) were housed in groups of four mice per cage
(eight mice per group) at 22 C with sequential light/dark cycle (lights off 6 pm) and were given free
access to diet and water. They were fed either the control diet (CT and CT-LPS groups; CE-2, CLEA Japan
Inc., Japan) or a CE-2 diet supplemented with 0.4% or 1% Qx (Qx 0.4%-LPS and Qx 1%-LPS groups) for 2
weeks. We have chosen to test two different doses (0.4% and 1%) since we have previously tested those
doses in models of obesity and/or diabetes (Ob/Ob mice, high-fat diet fed mice, streptozotocin-treated
mice). In fact, a supplementation of CoQ10 at 1% has been shown to decrease a panel of markers of
oxidative and inﬂammatory stress in the liver of high fat diet fed mice [19]. The energy content of the
CE-2 diet is 342 kcal/100 g. The CE-2 diet contained the following (g/100 g diet): moisture 8.7, protein
24.8, ﬁber 3.5, ash 7, lipid 4. Food intake, taking into account spillage, was recorded three times aweek.
The mean value for the weekly assessment of food and energy intake was calculated.
At the end of the feeding period, mice were ip injected with 0.1 mg/kg body weight of LPS (CT-LPS,
Qx 0.4%-LPS and Qx 1%-LPS groups) or NaCl 0.9% (CT group) and anaesthetized 1 h later by ip injection
of ketamine (100 mg/kg)/xylazine (10 mg/kg). Cava vein blood samples were collected in EDTA tubes,
and plasma was stored at 80 C. Liver was excised, immediately clamped in liquid N2 and kept at
80 C for mRNA analysis. The agreement of the animal experiments performed in this studywas given
by the local Ethical Committee and housing conditions were as speciﬁed by the Belgian Law of 29 May
2013, on the protection of laboratory animals (Agreement LA 1230314).
2.4. TNFa, PGE2 and nitrite measurements
PGE2 and TNFa concentrations were measured in frozen aliquots of incubation medium by
immunoassay kit. Nitrite concentration was measured by the Griess reaction as a reﬂection of NO$
production [3].
2.5. Real-time quantitative PCR
Total RNA was isolated from PCLS and liver using TriPure isolation reagent. cDNA was prepared by
reverse transcription of 1 mg total RNA using the Kit Reverse transcription System. Real-time poly-
merase chain reactions (PCRs) were performed with the StepOnePlus instrument and software
(Applied Biosystems) as described [20]. Ribosomal protein L19, RPL19, RNA was chosen as
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cyclooxygenase-2 (COX-2) and monocyte chemotactic protein-1 (MCP1) are available on request
(audrey.neyrink@uclouvain.be).2.6. Statistical analysis
Results are presented as Mean ± standard error of the mean (SEM). Statistical signiﬁcance of dif-
ference between groups was assessed by one-way followed by post hoc Tukey's multiple comparison
tests (GraphPad Prism Software; www.graphpad.com). Data with different superscript letters are
signiﬁcantly different (P < 0.05) according to the post hoc ANOVA statistical analysis.
3. Results
3.1. Effect of Qx towards LPS challenge performed in vitro using PCLS
TNFa, nitrite and PGE2 released in the medium and their related mRNA level (mRNA level of TNFa,
iNOS and COX2 respectively) have been analyzed as markers of inﬂammation. Incubation of PCLS in
control condition during 20 h versus 2 h increased TNFa, nitrites and PGE-2 release in the medium as
well as the expression of iNOS and COX2 mRNA, independently of the treatment. LPS induces a sig-
niﬁcant increase of TNFa released in the medium after 2 h and 20 h of incubation (Fig. 1A and B) and aFig. 1. Effect of LPS and Qx on TNFa released by PCLS (after 2 h e A- and 20 h e B) and TNFamRNA levels of PCLS (after 2 h e C- and
20 h e D). PCLS were incubated in the presence or absence of 100 mM Qx as well as in the presence or absence of 10 mg/ml LPS for 2 h
or 20 h. Medium were as following: control medium (CT), medium supplemented with Qx (Qx), medium supplemented with LPS
(CT-LPS) or medium supplemented with LPS and Qx (Qx-LPS). Data are mean ± SEM (n  4). Data with different superscript letters
are signiﬁcantly different p < 0.05, according to the post hoc ANOVA statistical analysis (One-way ANOVA). Qx, reduced form of
coenzyme Q10; LPS, lipopolysaccharide; PCLS, precision-cut liver slices; TNFa, tumor necrosis factor-a.
A.M. Neyrinck et al. / Clinical Nutrition Experimental 1 (2015) 10e1814signiﬁcant increase in TNFa mRNA level after 2 h, but not after 20 h (Fig. 1C and D). Qx does affect
neither TNFa release nor mRNA expression (Fig. 1).
Nitrite released in the medium is not modiﬁed by the treatments after 2 h of incubation (Fig. 2A),
but its level increased by LPS after 20 h, without any changes following Qx treatment (Fig. 2B). After 2 h
and 20 h of incubation (Fig. 2C and D), iNOS mRNA levels in PCLS shows the same pattern as nitrite
release after 20 h, while the LPS-promoted induction of iNOS is statistically signiﬁcant only after 20 h of
incubation. Nevertheless, Qx incubation does not modify iNOS expressionwhatever conditions (Fig. 2).
PGE2 released in the medium is increased after 2 h and 20 h of incubation with LPS but this
increased is only signiﬁcant after 2 h of incubation. PCLS incubated with Qx alone or Qx-LPS show
intermediary level -without signiﬁcance-between CT and LPS conditions (Fig. 3A and B). COX-2 mRNA
level is not modiﬁed by the treatments (Fig. 3C and D).
Nor LPS, neither Qx addition in the incubation medium induce AST release in the medium, signing
no cell lytic effect of the compounds at the tested dose. However, after 20 h of incubation, AST released
in themedium is increased as compared to 2 h values, independently of LPS and Qx treatment (data not
shown).
3.2. Effect of dietary enrichment with Qx towards LPS challenge performed in vivo
Markers of inﬂammation (TNFa, iNOS and COX-2 mRNA level), recruitment of macrophages (MCP1
mRNA level; Fig. 4) and toxicity (serum AST) have been assessed 1 h after LPS challenge (0.1 mg/kg, ip).
LPS injection induces a huge and signiﬁcant increase in liver TNFa, COX-2 and MCP-1 expression
(Fig. 4A, C, 4D); the induction of iNOS expression being not signiﬁcant (Fig. 4B). After 2 weeks of QxCT CT-LPS Qx QX-LPS
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Fig. 3. Effect of LPS and Qx on PGE2 released by PCLS (after 2 h e A- and 20 h e B) and COX-2 mRNA levels of PCLS (after 2 h eC- and
20 h e D). PCLS were incubated in the presence or absence of 100 mM Qx as well as in the presence or absence of 10 mg/ml LPS for 2 h
or 20 h. Medium were as following: control medium (CT), medium supplemented with Qx (Qx), medium supplemented with LPS
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A.M. Neyrinck et al. / Clinical Nutrition Experimental 1 (2015) 10e18 15dietary treatment, no signiﬁcant changes of the expression of LPS-induced inﬂammatory markers
occur, even at a dose of 1% of Qx. Of note, 1% Qx pretreatment tends to decrease AST level whereas LPS
injection does not modify serum AST level (AST level (means ± SEM in UI/L): CT 64.48 ± 10.04, CT-LPS
77.57 ± 20.50, Qx 0.4%-LPS 73.61 ± 17.65 and Qx 1%-LPS 40.02 ± 5.39).4. Discussion
The potential anti-inﬂammatory effect of CoQ10 or its reduced form has been suggested through
in vitro and in vivo studies [8]. From in-silico study (50 mM LPS on Caco-2 cells during 24 h), Schmelzer
et al. [21] showed the upregulation of genes controlling inﬂammation i.e. interleukine-5 or C reactive
protein. They observed in vitro the modulation of inﬂammatory cytokines such as TNFa in human
(THP-1) and murine monocyte (RAW264.7) cell lines after pretreatment with CoQ10 or Qx during 24 h
and LPS challenge (1 or 5 mg/ml during 4 h) [13,15,22]. Another group showed the suppression of
interleukin-1 (100 pg/ml)-induced inﬂammatory response in human dermal ﬁbroblasts incubated for
24 h together with interleukin-1 in the presence of CoQ10 (10 mM) [12]. Here, we have investigated for
the ﬁrst time the anti-inﬂammatory potential of Qx, the reduced form of CoQ10 on liver inﬂammation
induced by acute LPS challenge in the original model of PCLS maintain cell interactions. We conﬁrmed
that LPS challenge was able to produce inﬂammatory stress inside the liver tissue independently of any
cell lysis. Indeed, LPS induced the expression of TNFa upon short term incubation with LPS, leading to
the secretion of TNFa within 2 h of incubation; this effect being more pronounced after 20 h. Those
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observed an increase in iNOS mRNA 20 h after the incubation with LPS, and the relevance of this effect
was supported by the higher amount of nitrite (NO$ metabolite) released in the medium at that time
point. Elferink et al. showed an induction of iNOS mRNA expression ewithin a period of time ranging
from 3 h to 24 h of incubation in the presence of LPS in rat and human liver slices [23]. In vivo,
the kinetics of increased iNOS expression was observed after LPS challenge in the liver of mice, with a
100-fold increase remaining 6 and 18 h after the LPS challenge [24]. Interestingly, we could also show
an increase in the secretion of PGE2 by PCLS treated with LPS. This was coordinated with the changes in
COX-2 mRNA, and required also long-term incubation, in accordance with the previous data published
by Neyrinck et al. [3]. The higher production of PGE2 could contribute to the decrease in TNFa
expression observed after 20 h of incubation, as previously described [2]. Whatever the parameter
taken into account, wewere unable to showany signiﬁcant effect of Qx onmajor inﬂammatorymarkers
such as a cytokine eTNFa-, a prostaglandin ePGE2-or a nitrogen species e nitrite-released upon LPS
activation in our in vitro model.
Before concluding for the lack of anti-inﬂammatory effect of CoQ10 in the liver, we need to
investigate LPS challenge in vivo. Indeed, other mechanisms involving different organ interactions (for
A.M. Neyrinck et al. / Clinical Nutrition Experimental 1 (2015) 10e18 17example the contribution of the spleen [25]) or cell recruitment (monocytes and neutrophils) may
explain why the increase in TNFa mRNA expression upon LPS in PCLS remains really modest as
compared to the 100 fold increased in TNFamRNA expression observed in vivo 1 h after LPS injection in
this study. The same observation can be made concerning COX2: 1 h after the injection of LPS, liver
COX2 mRNA expression was 20 fold increased in this study, whereas we did not ﬁnd any changes in
these parameters upon LPS challenge in vitro. Therefore, we decided to test the implication of dietary
pretreatment with CoQ10 on mice. Indeed, promising data have been obtained in mice models of
obesity. In amodel of high-fat induced obesity associated with inﬂammation, we have shown that mice
fed orally with CoQ10 (1% in the diet during 8 weeks) exhibit a decrease in a panel of markers of
oxidative and inﬂammatory stress in the liver [19]. Furthermore, intraperitoneal injection of CoQ10
(10 mg/kg/day ip during 13 days) modulated the expression of pro-inﬂammatory cytokines in the
adipose tissue of ob/ob mice (decrease in TNFamRNA level) [26]. Even if the bioavailability of ingested
CoQ10 is low, we and others have shown that liver is a storage pool of CoQ10 [27,28]; COQ10 level being
40-fold higher following CoQ10 supplementation during 8 weeks at the dose of 1% in the diet [19].
In the present study, an acute load of LPS did not affect iNOS expression, but produced a huge in-
crease in the expression of TNFa and COX-2 in the liver. Those increases in COX-2 and TNFa expression
were associatedwith a recruitment of immune cells that can be dependent on the huge increase of liver
MCP1mRNA expression after LPS treatment. Pretreatment with Qx does not modify any key parameter
involved in inﬂammatory stress induced by an acute load of LPS. Those data contrast with our previous
data obtained in a model of high-fat fed mice with chronic low level inﬂammation, and showing that
Q10 was able to lessen a global hepatic inﬂammatory score, based on the mRNA level of TNFa,
interleukine-6, C reactive protein, STAMP2 and NADPH oxidase [19]. We can interpret those differences
through the fact that here we used a massive LPS dose mimicking a septic shock. This LPS condition is
really different of the low grade chronic inﬂammation observed in obese models. Several studies
performed in animals with acute inﬂammation induced by LPS suggest beneﬁcial effects due to CoQ10
supplementation (see [8] for review). For example, Abd El-Gawad and Khalifa showed that animals
with LPS-induced brain inﬂammation (10 mg/kg ip) are protected against oxidative stress (lipid per-
oxidation and nitric oxide production) after 7-days pretreatment with CoQ10 (200 mg/kg per os) [29].
Lelli et al. found a protective effect of CoQ supplementation on free-radical-mediated lipid peroxidation
assessed by ﬂuorescent products during septic shock in dogs [30]. Sugino et al. showed that CoQ10
supplementation could reduce the LPS-induced lipid peroxidation in mice, which might have been
associated with the enhanced survival of CoQ10-supplemented mice [31]. However, none of these
studies demonstrated a lower hepatic inﬂammation due to CoQ10 treatment.
In conclusion, Qx is not able to lessen inﬂammatory stress occurring upon acute LPS challenge in the
liver of rodents. However, in our experiment in vivo, we focused on the modiﬁcations of the expression
of genes coding for pro-inﬂammatory markers. As a perspective, it could be interesting to take into
account the fact that Qx is able to modulate post-transcriptional events, by changing namely the
miRNA-146a expression [32]. Anyway, CoQ10 remains an interesting anti-inﬂammatory nutrient in
certain contexts, since, for example, it can modulate liver inﬂammation in chronic pathologies char-
acterized by a low grade inﬂammation such as obesity.Conﬂict of interest
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